Market capitalization | GBP187.36b |
Enterprise Value | GBP208.41b |
PER (TTM) P/E ratio | 37.22 |
EV/FCF (TTM) EV/FCF | 30.95 |
EV/Sales (TTM) EV/Sales | 5.50 |
P/S ratio (TTM) P/S ratio | 4.94 |
P/B ratio (TTM) P/B ratio | 6.10 |
Dividend yield | 1.88% |
Last dividend (FY23) | GBP2.28 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
33 Analysts have issued a AstraZeneca forecast:
33 Analysts have issued a AstraZeneca forecast:
Mar '24 |
+/-
%
|
||
Turnover | 37,892 37,892 |
4%
4%
|
|
Gross income | 27,966 27,966 |
17%
17%
|
|
EBITDA | 10,707 10,707 |
15%
15%
|
EBIT (operating result) EBIT | 6,616 6,616 |
44%
44%
|
Net profit | 5,030 5,030 |
28%
28%
|
Figures in millions GBP.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Pascal Soriot |
Employees | 89,900 |
Founded | 1992 |
Website | www.astrazeneca.co.uk |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.